Shilpa Medicare receives approval of NorUDCA tablets for treatment of NAFLD in India

NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India

Merck presents positive Phase 2 data for Enpatoran demonstrating reduction in disease activity in patients with CLE and SLE with active lupus rash

Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8

Neuberg Diagnostics and Star Imaging form JV for Maharashtra’s largest integrated diagnostics network

For over 13 years, Star Imaging has pioneered the introduction of next-generation radiology technologies in Pune

Morepen to launch new fatty lever drug ‘Resmetirom’

Borosil Scientific to shift unit at Ambad to Bharuch

This will lead to the consolidation and optimization of the company's operations related to the manufacturing of ampoules and vials

KIMS partners with UAIMS Hospital

This strategic partnership will also enable KIMS to exercise call option (not an obligation) to acquire majority stake in UAIMS Hospital in the coming years

Indian doctor participates in Jordan’s first robotic radical hysterectomies

Shilpa Medicare announces positive outcome of Phase 3 studies of NorUDCA

Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India

Lilly's tirzepatide was superior to placebo for MASH resolution

SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine

Arvinas and Pfizer announce updated clinical data from Phase 1b Trial of Vepdegestrant in combination with Palbociclib

At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months